Polymorphisms of the β1-adrenergic receptor predict exercise capacity in heart failure

American Heart Journal

Volumn 144, Issue 5, 2002, Pages 840-846

  Wagoner, Lynne E ^a   Craft, Laura L ^a   Zengel, Paul ^a   McGuire, Nancy ^a   Rathz, Deborah A ^a   Dorn II, Gerald W ^a   Liggett, Stephen B ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; ARGININE; BETA 1 ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; GLYCINE; SERINE;

ADULT; ARTICLE; CONGESTIVE HEART FAILURE; EARLY DIAGNOSIS; EXERCISE; GENETIC POLYMORPHISM; GENOTYPE; HAPLOTYPE; HEART FAILURE; HEART FUNCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART RATE; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; OXYGEN CONSUMPTION; PRIORITY JOURNAL; RECEPTOR INTRINSIC ACTIVITY; CONGESTIVE CARDIOMYOPATHY; EXERCISE TOLERANCE; FEMALE; GENETIC MARKER; GENETICS; HEART MUSCLE ISCHEMIA; HETEROZYGOTE; HOMOZYGOTE; MALE; MIDDLE AGED; PATHOPHYSIOLOGY;

CARDIOMYOPATHY, DILATED; EXERCISE TOLERANCE; FEMALE; GENETIC MARKERS; HEART FAILURE, CONGESTIVE; HETEROZYGOTE; HOMOZYGOTE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA; OXYGEN CONSUMPTION; POLYMORPHISM, GENETIC; RECEPTORS, ADRENERGIC, BETA-1;

EID: 0036826922     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1067/mhj.2002.125325     Document Type: Article

References (31)

1. Brodde OE, Michel MC. Adrenergic and muscarinic receptors in the human heart. Pharmacol Rev 1999;51:651-90.
2. Bristow MR. Why does the myocardium fail? Insights from basic science. Lancet 1998;352:SI8-14.
3. Wellstein A, Belz GG, Palm D. Beta adrenoceptor subtype binding activity in plasma and beta blockade by propranolol and beta-1 selective bisoprolol in humans: Evaluation with Schild-plots. J Pharmacol Exp Ther 1988;246:328-37.
4. Bulbring E, Tomita T. Catecholamine action on smooth muscle. Pharmacol Rev 1987;39:49-96.
5. Liggett SB. β-adrenergic receptors in the failing heart: The good, the bad, and the unknown. J Clin Invest 2001,107:947-8.
6. 2-adrenergic receptor-mediated adenylate cyclase stimulation in nonfailing and failing human ventricular myocardium. Mol Pharmacol 1988;35: 295-303.
7. Parmley WW. Cost-effective cardiology: Cost-effective management of heart failure. Clin Cardiol 1996;19:240-2.
8. van Campen LC, Visser FC, Visser CA. Ejection fraction improvement by beta-blocker treatment in patients with heart failure: An analysis of studies published in the literature. J Cardiovasc Pharmacol 1998;32(1 Suppl):S31-5.
9. 2-adrenergic receptor determine exercise capacity in patients with heart failure. Circ Res 2000;86:834-40.
10. 2-adrenergic receptor polymorphism adversely affects the outcome of congestive heart failure. J Clin Invest 1998;102:1534-9.
11. 1-adrenergic receptor. J Biol Chem 1999;274:12670-4.
12. 1-adrenergic receptor polymorphisms: Analysis of c145A > G and c1165G > C. Hum Murat 1999;14: 271.
13. Rathz DA, Brown KM, Kramer LA, et al. Amino acid 49 polymorphisms of the human beta 1-adrenergic receptor affect agonistpromoted trafficking. J Cardiovasc Pharmacol 2002;39:155-60.
14. 2-adrenergic receptor within the fourth transmembrane domain alters ligand binding and functional properties of the receptor. J Biol Chem 1993;268:23116-21.
15. Small KM, Rathz DA, Liggett SB. Identification of adrenergic receptor polymorphisms. Methods Enzymol 2002;343:459-75.
16. Weber KT, Janicki JS, McElroy PA. Concepts and applications of cardiopulmonary exercise testing. Chest 1988;93:843-7.
17. 1-adrenergic receptor. Proc Natl Acad Sci USA 1987;84: 7920-4.
18. 2-adrenergic receptor: A protein with multiple membrane spanning domains and a chromosomal location shared with PDGF receptor gene. Proc Natl Acad Sci USA 1987;84:46-50.
19. Rands E, Candelore MR, Cheung AH, et al. Mutational analysis of β-adrenergic receptor glycosylation. J Biol Chem 1990;265:10759-64.
20. Benya RV, Kusui T, Katsuno T, et al. Glycosylation of the gastrinreleasing peptide receptor and its effect on expression, G protein coupling, and receptor modulatory processes. Mol Pharmacol 2000;58:1490-501.
21. Borjesson M, Magnusson Y, Hjalmarson A, et al. A novel polymorphism in the gene coding for the beta(1)-adrenergic receptor associated with survival in patients with heart failure. Eur Heart J 2000;21:1810-2.
22. 1-adrenoceptor gene and evaluation of its role in idiopathic dilated cardiomyopathy. J Mol Cell Cardiol 1999;31:1025-32.
23. 2-adrenergic receptor in nocturnal and non-nocturnal asthma: Evidence that Gly16 correlates with the nocturnal phenotype. J Clin Invest 1995;95:1635-41.
24. 2-adrenoceptor polymorphism with lower airway reactivity in asthmatic subjects. Lancet 1995;345:1213-4.
25. 2-adrenergic receptor on the response to regular use of albuterol in asthma. Amer J Respir Crit Care Med 2000;162:75-80.
26. 2-adrenergic receptor haplotypes alter receptor expression and predict in vivo responsiveness. Proc Natl Acad Sci USA 2000;97:10483-8.
27. 1-adrenoceptor polymorphism varies in frequency among different ethnic groups but does not alter response in vivo. Pharmacogenetics 2001;11: 191-7.
28. 1-adrenoceptor polymorphism in humans. Pharmacogenetics 2001;11:199-205.
29. 1-adrenergic receptor gene and hypertension. Circ 2001; 104:187-90.
30. Mancini CM, Eisen H, Kussmaul W, et al. Value of peak exercise oxygen consumption for optimal timing of cardiac transplantation in ambulatory patients with heart failure. Circ Res 1991;83:778-86.
31. Osada N, Chairman B, Miller L, et al. Cardiopulmonary exercise testing identifies low risk patients with heart failure and severely impaired exercise capacity considered for heart transplantation. J Am Coll Cardiol 1998;31:577-82.